SCHEMBL14026864

SCHEMBL14026864

[2H]C([2H])(O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.56
ACP3 P15309 1/20 0.56
IDO1 P14902 2/20 0.55
HTR2A P28223 2/20 0.53
HTR2B P41595 2/20 0.53
HTR2C P28335 1/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
MIF P14174 2/20 0.50
PRKCA P17252 1/20 0.49
PRKCD Q05655 1/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 2/20 0.47
GRIN2B Q13224 2/20 0.47
EPHX1 P07099 1/20 0.47
MAOB P27338 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2257 0.83 TAAR1 (0.60) TAAR1ACP3IDO1HTR2AHTR2B
SCHEMBL12702506 0.82 TAAR1 (0.59) TAAR1ACP3IDO1HTR2AHTR2B
SCHEMBL12702476 0.82 ACP3 (0.50) TAAR1ACP3IDO1HTR2AHTR2B
SCHEMBL12702477 0.82 MEN1 (0.51) TAAR1ACP3IDO1HTR2AHTR2B
SCHEMBL12702466 0.82 ACP3 (0.50) TAAR1ACP3IDO1HTR2AHTR2B
SCHEMBL27370336 0.82 TAAR1 (0.58) TAAR1ACP3IDO1HTR2AHTR2B
SCHEMBL156739 0.80 TAAR1 (0.67) TAAR1ACP3IDO1HTR2AHTR2B
SCHEMBL14026863 0.80 TAAR1 (0.56) TAAR1ACP3IDO1HTR2AHTR2B
SCHEMBL29696946 0.80 TAAR1 (0.56) TAAR1ACP3IDO1HTR2AHTR2B
SCHEMBL30525290 0.80 TAAR1 (0.67) TAAR1ACP3IDO1HTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4003344-A1 DEUTERATED MK2 PATHWAY INHIBITORS AND METHODS OF USING THE SAME Aclaris Therapeutics, Inc. (US) 2022-06-01 EP disclosed
US-20080261926-A1 Pharmaceutical Calcimimetics CONCERT PHARMACEUTICALS INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261926-A1 Pharmaceutical Calcimimetics CASR, CALCR, PTH1R TAAR1 927/4885ACP3 159/4885IDO1 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.